Author

Bismark Amofah

Institution: AstraZeneca (United Kingdom)

Observed institutions: AstraZeneca (United Kingdom), AstraZeneca (United States)

ORCID: 0009-0001-3663-772X

Observed ORCID: 0009-0001-3663-772X

OpenAlex ID: A5116832169

Accelerating high-concentration monoclonal antibody development with large-scale viscosity data and ensemble deep learning

2025 · Lateefat A. Kalejaye, Jia-Min Chu, et al. · mAbs · 24

Improving dual targeting selectivity in T-cell engagers via synapse-gated and affinity-tuned trispecific antibody design

2025 · Peng Zhao, John Schardt, et al. · mAbs · 9

Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape

2025 · Fangqiang Zhu, Saravanan Rajan, et al. · Science Advances · 6

Predicting antibody self-association with sequence–structure fusion models: the central role of CSI-BLI in early developability screening

2026 · Shafayat Ahmed, Federico Devalle, et al. · mAbs · 1

Predicting non-specific binding of VHHs using machine learning models with cluster-aware validation

2026 · Valentin Stanev, Federico Devalle, et al. · mAbs

Works count: 5

Citation count: 40

H-index: 3

I10-index: 1